Enasidenib, a targeted inhibitor of IDH2 mutations, was approved by the United States Food and Drug Administration to treat relapsed or refractory AML in August 2017 and is under study for other indications [8–11]. The gene discussed is IDH2; the disease is acute myeloid leukemia.